

**GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS AND FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA
UNSTARRED QUESTION NO. †5701
TO BE ANSWERED ON THE 27TH MARCH 2026

Biopharma Shakti Scheme

†5701. Shri Haribhai Patel:

Will the Minister of **CHEMICALS AND FERTILIZERS** be pleased to state:

- (a) whether the Biopharma strategy SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovations) Scheme is being implemented by the Government;
- (b) if so, the details thereof;
- (c) the details of the financial allocation made under the said scheme, State-wise and yearwise; and
- (d) the manner in which biopharmaceutical manufacturing and research centres are likely to be upgraded to global standards under the said scheme?

ANSWER

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS

(SMT. ANUPRIYA PATEL)

(a) to (d): With a view to strengthen the domestic biopharmaceutical sector and enhance global competitiveness in biologics and biosimilars, the Government has announced the Biopharma SHAKTI scheme with an outlay of ₹10,000 crore over five years with an objective to build a globally competitive domestic ecosystem for biologics and biosimilars to support affordable healthcare in India and enable India to emerge as a global biopharma manufacturing and innovation hub.

Under the scheme, it is envisaged to enable faster, globally credible approvals by strengthening the CDSCO through creation of a dedicated Scientific Review Cadre of reviewers and specialist positions for advanced fields. It is also envisaged to expand India's clinical research footprint by creating a nationally accredited network of 1,000 clinical trial sites under ICMR. The initiative envisages to build the ecosystem for domestic production of biologics and biosimilars. Further by supporting research and development, strengthening clinical trial infrastructure and promoting collaboration between academia, research institutions and industry, the Scheme seeks to encourage domestic innovation and manufacturing capabilities in the biopharmaceutical sector. Such initiatives are expected to contribute towards reducing import dependence over time and enhance India's participation in the global biopharmaceutical market.
